Beilu Pharmaceutical (300016.SZ) obtained the drug registration certificate for Bimatoprost Eye Drops.

Zhito Finance APP News, Beilu Pharmaceutical (300016.SZ) announced that recently, the company received the "Drug Registration Certificate" for Bimatoprost Eye Drops approved and issued by the National Medical Products Administration. The original research enterprise of Bimatoprost Eye Drops is Allergan of the United States, and it is used to reduce intraocular pressure in patients with open-angle glaucoma and ocular hypertension. Bimatoprost Eye Drops was approved as a Category 4 chemical drug, deemed to have passed the generic drug quality and efficacy consistency evaluation, further enriching the company's formulation product pipeline and achieving product layout in the ophthalmology field.